The studies reported here clearly demonstrate Vitalife to be a highly efficacious method of GH therapy that addresses the problems associated with the injectable recombinant growth hormone, bringing us one step closer to achieving the next breakthrough in the fight against advancing age. In particular, the ability of Vitalife to decrease IGF-1 levels is a huge step forward, since IGF-1 levels are known to peak in the initial stages of cancer. While IGF-1 still remains a subject of controversy, any therapeutic measure would do well to not increase its presence any further in serum.
How does Vitalife exert its physiologic and life extending properties at the cellular level? Most recent studies on GH therapy have assumed that role to ironically belong to IGF-1, which is, from the physiological point of view, an important intermediate for several cellular functions including division, differentiation etc. However, the inverse relationship between GH and IGF-1 levels characteristic of Vitalife treatment, refutes this philosophy and requires new research to be initiated in this area. For example, could Vitalife have a role in mitochondrial biogenesis, similar to the effects observed in calorically restricted mice? Can it be used in conjunction with caloric restriction to extend life? In fact, in collaboration with researchers at the North Carolina State University, we are currently seeking to revolutionize our understanding of the anti-aging process. To that end, we have initiated preclinical trials in mice, in an attempt to take our understanding of Vitalife function to the next level.
The knowledge that Vitalife could directly impact the biogenesis of the cellular energy factories, independent of caloric restrictions and other factors, would be a revelation with regard to its mode of action, and also a massive contribution to the development of novel anti-aging strategies.
This document is divided in four chapters. Please click on your choice
